Lauren Wiebe, MD
Assistant Professor of Medicine
Dr. Lauren Wiebe joined the Medical College of Wisconsin faculty in 2010 as an Assistant Professor of Medicine in the Division of Hematology and Oncology. Dr. Wiebe specializes in gastrointestinal oncology with an additional focus on palliative medicine. Her interests include hepatocellular carcinoma, biliary tract cancers, gastrointestinal stromal tumors, as well as pancreas and neuroendocrine cancers.
After attending Harvard University as an undergraduate, Dr. Wiebe graduated from the Columbia University College of Physicians and Surgeons in 2004. She completed both her internal medicine residency and fellowship in medical oncology at the University of Chicago. In 2008, Dr. Wiebe received the ASCO Foundation Merit Award for an oral abstract of a phase ll trial in gastrointestinal stromal tumors (GIST). She also completed a concurrent fellowship in Clinical Medical Ethics at the MacLean Center at the University of Chicago. Most recently, Dr. Wiebe completed an additional fellowship in palliative medicine at Northwestern University prior to joining the faculty at the Medical College of Wisconsin.
Wiebe L, and Von Roenn JH, Optimizing Palliative Care of Patients with Advanced Pancreatic Cancer, Oncology, 23(12, supp 4): 28-33, 2009
Wiebe L, Kasza K, Maki RG, D'Adamo DR, Chow WA, Wade JL, Agamah E, Stadler WM, Vokes EE, Kindler HL, Sorafenib (SOR) is active in patients with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase ll Consortium, Journal of Clinical Oncology, 26: May 20 supl; abstract #10502, 2008*
*Also cited in ASCO Clinical Cancer Advances 2008, p 23
Landry DW, Zucker H, Sauer M, Reznick M, and Wiebe L, Hypocellularity and absence of compaction as criteria for embryonic death, Regenerative Medicine. 1(3):361-71, 2006
Papadopoulos KP, Noguera-Irizarry W, Wiebe L, Hesdorffer CS, Garvin J, Nichols GL, Vahdat LH, Lo KM, Skerrett D, Bernstein D, Sharpe E, Savage DG, Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma, Bone Marrow Transplantation, 36(6):491-7, 2005